BMP2 induces osteogenic differentiation through ACKR3 in mesenchymal stem cells

• Published in: Biochemical and biophysical research communications Vol. 664; pp. 59 - 68
• Main Authors: Liu, Jiang, Yao, Xin-Tong, Feng, Xiao-Lei, Bai, Xi-Zhuang
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 05.07.2023
• Subjects: ACKR3; Animals; Bone and Bones - metabolism; Bone Morphogenetic Protein 2 - metabolism; Cell Differentiation; Cells, Cultured; Humans; Mesenchymal Stem Cells; Mice; Osteoblasts - metabolism; Osteogenesis; Osteogenic differentiation; p38/MAPK signaling; p38/MAPK signaling; MSCs; ALP; ACKR3; OPN; Osteogenic differentiation; Mesenchymal stem cells; Runx2
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2023.04.097

In recent years, bone loss related diseases have attracted more and more attention, such as osteoporosis and osteonecrosis of the femoral head exhibited symptoms of osteopenia or insufficient bone mass in a certain stage. Mesenchymal stem cells (MSCs), which can be induced to differentiate into osteoblasts under certain conditions can provide a new solution bone disease. Herein, we deciphered the possible mechanism by which BMP2 drives the transduction of MSCs to the osteoblast lineage through ACKR3/p38/MAPK signaling. The levels of ACKR3 in femoral tissues of samples from humans with different ages and sexes were measured firstly and found that ACKR3 protein levels increase with age. In vitro cellular assays showed that ACKR3 inhibits BMP2-induced osteo-differentiation and promotes adipo-differentiation of MSCs, whereas siACKR3 exhibited the opposite effects. In vitro embryo femur culture experiment showed that inhibition of ACKR3 enhanced BMP2-induced trabecular bone formation in C57BL6/J mouse. In terms of molecular mechanisms, we found that p38/MAPK signaling might play the key role. ACKR3 agonist TC14012 suppressed the phosphorylation of p38 and STAT3 in BMP2 induced MSCs differentiation. Our findings suggested that ACKR3 might be a novel therapeutic target for the treatment of bone-associated diseases and bone-tissue engineering. •ACKR3 inhibits the osteo-differentiation of mesenchymal stem cells is proposed.•The mechanism relies on p38/MAPK signaling and BMP2.•Validated in SD rats, C57BL6/J mice, human bone tissues and in vitro experiments.